Oxford-AstraZeneca Nasal COVID-19 Vaccine Falters in Clinical Trial
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
Oxford-AstraZeneca Nasal COVID-19 Vaccine Falters in Clinical Trial
Oxford-AstraZeneca Nasal COVID-19 Vaccine Falters in Clinical Trial
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
Evidence thus far shows that pregnant people infected with SARS-CoV-2 are at higher risk for severe disease and death, as well as complications in their pregnancies.
Early reports that Omicron causes less-severe disease than Delta seem to be borne out, but it’s not yet clear to what extent that’s due to the variant itself versus the populations it’s infecting.
By avoiding the production of antibodies, something vaccines ordinarily induce, the immunization sidesteps the problem of antibody-dependent enhancement, which can amplify infection by a similar virus and is known to occur with dengue and Zika.
Rollouts of the shot have ground to a halt following reports of blood clots, but health authorities say that these fears are unfounded and vaccination programs should continue.